Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab
ESMO Congress 2025
Andrew R. Clamp, MD, PhD, of The Christie NHS Foundation Trust, reviews results of the phase III ICON8B trial, which found that in patients with high-risk stage III to IV epithelial ovarian cancer, the use of dose-dense weekly paclitaxel in combination with every-3-week carboplatin and bevacizumab as first-line systemic therapy improved median overall survival compared to standard every-3-week dosing (Abstract 1064O).
The ASCO Post Staff
Emese Zsiros, MD, PhD, of Roswell Park Comprehensive Cancer Center, reviews results from the randomized, double-blind, phase III ENGOT-ov65/KEYNOTE-B96 trial. According to the study investigators, “Pembrolizumab in combination with weekly paclitaxel with or without bevacizumab demonstrated statistically significant and clinically meaningful improvement in progression-free survival regardless of PD-L1 status and in overall survival in participants with PD-L1–expressing tumor (CPS ≥ 1).... This is the first phase III study to report a statistically significant improvement in overall survival with an immune checkpoint inhibitor–based regimen in ovarian cancer.” (Abstract LBA3)
